May 14, 2022

Bridge to Life Ltd. Receives FDA Breakthrough Device Designation

Bridge to Life Advances Infusion System Development with Breakthrough Device Designation for the LifeCradle® Transport system for the preservation of the heart.

NORTHBROOK, Ill., April 21, 2022 /PRNewswire/ — Bridge to Life, Ltd. (“Bridge to Life” or the “Company”), a leading global provider of organ preservation solutions and organ perfusion technologies, announced breakthrough device designation clearance from the Food and Drug United States Administration (FDA) for its LifeCradle® Transport system for the preservation of the heart.

The cradle of life® The Heart Preservation Transport System enables the preservation, storage, monitoring and transport of donor hearts using hypothermic, oxygen and nutrient infusion from organ retrieval through transplantation at the receiver.

The cradle of life® The Heart Preservation Transport System offers clinicians the ability to cost-effectively implement hypothermic oxygenated perfusion of heart grafts during graft transport from the donor site to the transplant center operating room. The inherently intuitive system uses a plug-and-play design for a streamlined workflow facilitating easy setup and minimal user overhead. The system uses Belzer MPS® UW Machine Perfusion Perfusate solution requiring no blood or blood products.

“LifeCradle opens a window into the future of long-term cardiac storage and transport, so that a heart of Miami can fly to Seattle and be implanted,” said Richard BirchBridge to Life Vice President of Business Development.

“Bridge to Life continues to research and develop technologies to improve organ preservation and has now added organ infusion devices, including liver, kidney, lung and heart, to our product portfolio. said Stevan Schweighardt, President and CEO of Bridge to Life. “The addition of perfusion technology provides more and better organs to the global transplant community.”

About Bridge to Life
Bridge to Life was founded with a mission to improve organ transplants by licensing and developing new preservation solutions and technologies to provide the highest quality service to organ procurement organizations and centers. transplantation. The American company, headquartered in Northbrook, Ill., is a leading preservation solution provider in the world, focused on innovation in organ preservation and machine perfusion. With a strong emphasis on collaboration with surgeons and transplant professionals, he continues to explore emerging science and preservation technologies. Visit bridgetolife.com to learn more.

Media Contact:
chuck allen
720-320-1192

SOURCE Bridge to Life Ltd.